% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Janssens:120496,
      author       = {G. O. Janssens and L. Gandola and S. Bolle and H.
                      Mandeville and M. Ramos-Albiac and K. van Beek and H.
                      Benghiat and B. Hoeben and A. Morales La Madrid and R.-D.
                      Kortmann and D. Hargrave and J. Menten and E. Pecori and V.
                      Biassoni and A. O. von Bueren and D. G. van Vuurden and M.
                      Massimino and D. Sturm$^*$ and M. Peters and C. M. Kramm},
      title        = {{S}urvival benefit for patients with diffuse intrinsic
                      pontine glioma ({DIPG}) undergoing re-irradiation at first
                      progression: {A} matched-cohort analysis on behalf of the
                      {SIOP}-{E}-{HGG}/{DIPG} working group.},
      journal      = {European journal of cancer},
      volume       = {73},
      issn         = {0959-8049},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2017-00925},
      pages        = {38 - 47},
      year         = {2017},
      abstract     = {Overall survival (OS) of patients with diffuse intrinsic
                      pontine glioma (DIPG) is poor. The purpose of this study is
                      to analyse benefit and toxicity of re-irradiation at first
                      progression.At first progression, 31 children with DIPG,
                      aged 2-16 years, underwent re-irradiation (dose
                      19.8-30.0 Gy) alone (n = 16) or combined with systemic
                      therapy (n = 15). At initial presentation, all patients
                      had typical symptoms and characteristic MRI features of
                      DIPG, or biopsy-proven high-grade glioma. An interval of
                      ≥3 months after upfront radiotherapy was required before
                      re-irradiation. Thirty-nine patients fulfilling the same
                      criteria receiving radiotherapy at diagnosis, followed by
                      best supportive care (n = 20) or systemic therapy
                      (n = 19) at progression but no re-irradiation, were
                      eligible for a matched-cohort analysis.Median OS for
                      patients undergoing re-irradiation was 13.7 months. For a
                      similar median progression-free survival after upfront
                      radiotherapy (8.2 versus 7.7 months; P = .58), a
                      significant benefit in median OS (13.7 versus 10.3 months;
                      P = .04) was observed in favour of patients undergoing
                      re-irradiation. Survival benefit of re-irradiation increased
                      with a longer interval between end-of-radiotherapy and first
                      progression (3-6 months: 4.0 versus 2.7; P < .01; 6-12
                      months: 6.4 versus 3.3; P = .04). Clinical improvement
                      with re-irradiation was observed in 24/31 $(77\%)$ patients.
                      No grade 4-5 toxicity was recorded. On multivariable
                      analysis, interval to progression (corrected hazard
                      ratio = .27-.54; P < .01) and re-irradiation (corrected
                      hazard ratio = .18-.22; P < .01) remained prognostic for
                      survival. A risk score (RS), comprising 5 categories, was
                      developed to predict survival from first progression (ROC:
                      .79). Median survival ranges from 1.0 month (RS-1) to 6.7
                      months (RS-5).The majority of patients with DIPG, responding
                      to upfront radiotherapy, do benefit of re-irradiation with
                      acceptable tolerability.},
      cin          = {B062},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331},
      pnm          = {312 - Functional and structural genomics (POF3-312)},
      pid          = {G:(DE-HGF)POF3-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28161497},
      doi          = {10.1016/j.ejca.2016.12.007},
      url          = {https://inrepo02.dkfz.de/record/120496},
}